RIM
ECYT

RS Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

RS Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-470,800
Closed -$11.2M – 416
2014
Q1 		$11.2M Sell
470,800
-39,600
-8% -$574K 0.07% 225
2013
Q4 		$5.46M Buy
510,400
+30,100
+6% +$332K 0.03% 253
2013
Q3 		$6.4M Buy
+480,300
New +$7.59M 0.04% 230

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RS Investment Management's ECYT Position: Q2 2014 in Review

RS Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2014, closing a stake of 470,800 shares — an estimated $11.2M sold.

RS Investment Management first reported a position in ECYT in Q3 2013 and held it in 3 quarters. The position peaked at $11.2M in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q2 2014.

  • RS Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • RS Investment Management sold 470,800 Endocyte, Inc. Common Stock shares in Q2 2014, an estimated $11.2M.
  • RS Investment Management first reported a position in Endocyte, Inc. Common Stock in Q3 2013 and held it in 3 quarters.
  • RS Investment Management's Endocyte, Inc. Common Stock position peaked at $11.2M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2014.

Based on RS Investment Management's 13F filing for Q2 2014, filed 15 Aug 2014.